Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Insmed Inc INSM

Healthcare Biotechnology
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).


NDAQ:INSM - Post by User

Insmed Inc
<< Previous
 Bullboard Posts
User Avatar Image
(119)
•••
Post by whytestockson Jun 21, 2024 2:00pm
24 Views
Post# 36100416

Outperform Recommendation Issued On INSM By Evercore ISI

Outperform Recommendation Issued On INSM By Evercore ISI
NEWS: $INSM Outperform Recommendation Issued On INSM By Evercore ISI2024-06-21 09:15:03 ET Evercore ISI analyst issues OUTPERFORM recommendation for INSM on June 21, 2024 08:10AM ET. The previous analyst recommendation was Outperform. INSM was trading at $64.71 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...INSM - Outperform Recommendation Issued On INSM By Evercore ISI

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities